Serum Beta‐Hydroxybutyrate as a Biomarker for Predicting Major Adverse Cardiovascular Events After Type a Aortic Dissection Surgery
World Journal of Surgery · 2026
DOI: 10.1002/wjs.70520 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift World Journal of Surgery, 2026. Verfasst von Jian Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, West China Hospital of Sichuan University, Sichuan, China. Hauptthemen laut MEDLINE: 3-Hydroxybutyric Acid, Dissection, Ascending Aorta, Postoperative Complications. Die Arbeit nennt 37 Literaturangaben. Gefördert von: natural science foundation of the science and technology department of sichuan province, "135″ project of West China Hospital, Sichuan University.
Abstract (Originalsprache)
Background
Acute type A aortic dissection (ATAAD) is a life‐threatening cardiovascular emergency, and major adverse cardiovascular events (MACE) are common postoperative complications. However, reliable biomarkers for predicting MACE remain lacking. This study evaluated the prognostic value of serum beta‐hydroxybutyrate ( β ‐OHB) in predicting MACE after ATAAD surgery.
Methods
A retrospective observational study analyzed 728 surgically treated ATAAD patients from West China Hospital (2020–2024). Patients were stratified by preoperative β ‐OHB levels. The primary endpoint was in‐hospital MACE (all‐cause mortality, myocardial infarction, heart failure, repeat surgery, or stroke); secondary endpoints included 30‐day mortality and ICU/hospital stay duration.
Results
Elevated β ‐OHB levels independently predicted higher MACE risk (adjusted OR: 8.314, 95% CI: 4.149–16.659, p < 0.001) and 30‐day mortality (adjusted HR: 2.316, 95% CI: 1.522–3.524, p < 0.001). ROC analysis showed β ‐OHB (AUC: 0.781) was not inferior to conventional biomarkers (BNP, D‐dimer) in predicting the occurrence of MACE. High β ‐OHB (≥ 0.30 mmol/L) correlated with increased MACE incidence (5.2% vs. 9.0% vs. 31.9%, p < 0.001) and lower 30‐day survival (100% vs. 96.2% vs. 89.0%, log‐rank p < 0.001) when patients were divided into three groups based on serum β ‐OHB levels: low β ‐OHB group (< 0.15 mmol/L, n = 287), intermediate β ‐OHB group (0.15–0.30 mmol/L, n = 212), and high β ‐OHB group (≥ 0.30 mmol/L, n = 229). Conclusions β ‐OHB is a novel metabolic biomarker for postoperative risk stratification in ATAAD, with potential clinical utility in guiding decision‐making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, West China Hospital of Sichuan University, Sichuan, China.
- Department of Anesthesiology, Laboratory of Anesthesia and Critical Care Medicine, National-Local Joint Engineering Research Centre of Translational Medicine of Anesthesiology, West China Hospital, Sichuan University, C…
ORCID-Profile: Xuehan Li
Förderung
- natural science foundation of the science and technology department of sichuan province
- "135″ project of West China Hospital, Sichuan University
Zitieren
APA
Zhou, J., Xu, L., Yang, T., He, M., Wang, R., Ke, B., & Li, X. (2026). Serum Beta‐Hydroxybutyrate as a Biomarker for Predicting Major Adverse Cardiovascular Events After Type a Aortic Dissection Surgery. World Journal of Surgery. https://doi.org/10.1002/wjs.70520
Vancouver
Zhou J, Xu L, Yang T, He M, Wang R, Ke B, et al. Serum Beta‐Hydroxybutyrate as a Biomarker for Predicting Major Adverse Cardiovascular Events After Type a Aortic Dissection Surgery. World Journal of Surgery. 2026. doi:10.1002/wjs.70520
BibTeX
@article{Zhou2026,
author = {Zhou, Jian and Xu, Liuyan and Yang, Taoran and He, Menglin and Wang, Rurong and Ke, Bowen and Li, Xuehan},
title = {Serum Beta‐Hydroxybutyrate as a Biomarker for Predicting Major Adverse Cardiovascular Events After Type a Aortic Dissection Surgery},
journal = {World Journal of Surgery},
year = {2026},
doi = {10.1002/wjs.70520}
}
EUVIMED